Dividends Inside Welcome to Dividends Inside
Welcome to Dividends Inside!
The platform is currently in beta, so some features and data may still change as we improve the service. If you have questions, feedback, or run into anything unexpected, please contact us at info@dividendsinside.com.
Welcome to Dividends Inside!
The platform is currently in beta, so some features and data may still change as we improve the service. If you have questions, feedback, or run into anything unexpected, please contact us at info@dividendsinside.com.
Agomab Therapeutics NV
AGMB
$10.66 (+ $0.31 + 3.00%)
Last updated: Previous Close (2026-04-15)
About the Company
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company developing novel disease-modifying therapies for immunology and inflammatory diseases, with a primary focus on chronic fibrotic indications that have high unmet medical needs. The company targets key pathways like the transforming growth factor β (TGFβ) to resolve fibrosis and restore organ function, utilizing small molecules and antibodies designed for enhanced efficacy and reduced systemic toxicities. Its lead pipeline includes Ontunisertib (AGMB-129), an oral small molecule inhibitor of ALK5/TGFβR1 in Phase 2a trials for fibrostenosing Crohn’s disease; AGMB-447, an inhaled inhibitor in Phase 1 for idiopathic pulmonary fibrosis; and AGMB-101, a preclinical HGF-mimetic monoclonal antibody showing antifibrotic and regenerative potential via MET receptor agonism. AgomAb Therapeutics NV retains worldwide rights to its programs, addressing large markets in gastrointestinal, pulmonary, and other fibrotic disorders. Founded in 2017 and headquartered in Antwerp, Belgium, the company employs 58 people led by CEO Tim Knotnerus. It plays a significant role in the biotechnology sector by advancing targeted therapies against fibrotic diseases, supported by recent capital raises to fuel clinical progression.
Price History
Latest News for AGMB
Agomab to Participate in Upcoming Conferences
Antwerp, Belgium, May 14, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced that members of the management team will participate in the following upcoming industry and investor conferences: ATS International Conference 2026. Poster Board #904 titled ‘AGMB-447, an Inhaled Lung-Restricted TGFβR1/ALK5 Inhibitor Intended for the Treatment of Idiopathic Pulmonary Fibrosis, Shows Robust Anti-Fibrotic Activ
Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook
-- Cash and Cash Investments at December 31, 2025 of €116.5 Million and Gross Proceeds of $208 Million from Initial Public Offering (IPO) Expected to Extend Cash Runway into First Half of 2029 -- -- Positive Interactions with U.S. Food and Drug Administration (FDA) on Design of Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease (FSCD) ---- On Track to Initiate Phase 2b Study in FSCD with Ontunisertib and Phase 2 Study in Idiopathic Pulmonary Fibrosis (IPF) with AGMB-447 in Second
AgomAb Therapeutics (AGMB) Wins U.S. Patent for AGMB-447
AgomAb Therapeutics NV (NASDAQ:AGMB) is one of the 7 Best Strong Buy European Stocks to Invest In. On March 26, 2026, AgomAb Therapeutics NV (NASDAQ:AGMB) announced that the U.S. Patent and Trademark Office granted U.S. Patent No. 12,577,230 covering the composition of matter for AGMB-447. The company said AGMB-447 is an investigational inhaled, lung-restricted small […]
Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis
Antwerp, Belgium, March 26, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“’Agomab’”), a clinical-stage biopharmaceutical company focused on fibrosis, today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 12,577,230, covering the composition of matter of AGMB-447, to Agomab. AGMB-447 is the company’s investigational inhaled lung-restricted small molecule inhibitor of ALK5 (or TGFβR1), currently in a Phase 1b study for the treatment of Idiopathic P
European Equities Traded in the US as American Depositary Receipts Higher Wednesday
European equities traded in the US as American depositary receipts were rising on Wednesday morning,
Agomab Announces Closing of Initial Public Offering
ANTWERP, Belgium, February 9, 2026 (GLOBE NEWSWIRE) – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need, today announced the closing of its previously announced initial public offering of 12,500,000 American Depositary Shares (“ADSs”) representing 12,500,000 of its common sha